Literature DB >> 28591526

Pembrolizumab for Advanced Urothelial Carcinoma.

Joaquim Bellmunt1, Dean F Bajorin2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28591526     DOI： 10.1056/NEJMc1704612

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

1.  Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.

Authors:  Dylan J Martini; Yuan Liu; Julie M Shabto; Colleen Lewis; Meredith R Kline; Hannah Collins; Mehmet Akce; Haydn T Kissick; Bradley C Carthon; Walid L Shaib; Olatunji B Alese; Rathi N Pillai; Conor E Steuer; Christina S Wu; David H Lawson; Ragini R Kudchadkar; Viraj A Master; Bassel F El-Rayes; Suresh S Ramalingam; Taofeek K Owonikoko; R Donald Harvey; Mehmet Asim Bilen
Journal:  Invest New Drugs       Date:  2019-02-06       Impact factor: 3.850

2.  Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.

Authors:  Shira Peleg Hasson; Benjamin Salwen; Ayelet Sivan; Sivan Shamai; Ravit Geva; Ofer Merimsky; Ari Raphael; Haim Shmilovich; Yonatan Moshkovits; Livia Kapusta; Zach Rozenbaum; Ido Wolf; Michal Laufer-Perl
Journal:  Clin Res Cardiol       Date:  2020-04-15       Impact factor: 5.460

3.  Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.

Authors:  Dan Sha; Zhaohui Jin; Jan Budczies; Klaus Kluck; Albrecht Stenzinger; Frank A Sinicrope
Journal:  Cancer Discov       Date:  2020-11-02       Impact factor: 38.272

Review 4.  Combination of CTLA-4 and PD-1 blockers for treatment of cancer.

Authors:  Anand Rotte
Journal:  J Exp Clin Cancer Res       Date:  2019-06-13

Review 5.  The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma.

Authors:  Tucci Marco; Passarelli Anna; Todisco Annalisa; Mannavola Francesco; Stucci Luigia Stefania; D'Oronzo Stella; Rossini Michele; Taurisano Marco; Gesualdo Loreto; Silvestris Franco
Journal:  Ther Adv Med Oncol       Date:  2019-09-24       Impact factor: 8.168

6.  A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma.

Authors:  Amin H Nassar; Kent W Mouw; Opeyemi Jegede; Atul B Shinagare; Jaegil Kim; Chia-Jen Liu; Mark Pomerantz; Lauren C Harshman; Eliezer M Van Allen; Xiao X Wei; Bradley McGregor; Atish D Choudhury; Mark A Preston; Fei Dong; Sabina Signoretti; Neal I Lindeman; Joaquim Bellmunt; Toni K Choueiri; Guru Sonpavde; David J Kwiatkowski
Journal:  Br J Cancer       Date:  2019-12-20       Impact factor: 7.640

7.  Angiogenesis related gene expression significantly associated with the prognostic role of an urothelial bladder carcinoma.

Authors:  Jianfeng Wang; Meng Guo; Xiaofeng Zhou; Zhenshan Ding; Xing Chen; Yangtian Jiao; Wenwei Ying; Shuang Wu; Xiaoyun Zhang; Na Geng
Journal:  Transl Androl Urol       Date:  2020-10

Review 8.  Approved checkpoint inhibitors in bladder cancer: which drug should be used when?

Authors:  Pooja Ghatalia; Matthew Zibelman; Daniel M Geynisman; Elizabeth Plimack
Journal:  Ther Adv Med Oncol       Date:  2018-07-30       Impact factor: 8.168

Review 9.  Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4.

Authors:  Joaquim Bellmunt
Journal:  Biomedicines       Date:  2018-08-02

10.  Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin.

Authors:  Akihito Hashizume; Susumu Umemoto; Tomoyuki Yokose; Yoshiyasu Nakamura; Mitsuyo Yoshihara; Kahori Shoji; Satoshi Wada; Yohei Miyagi; Takeshi Kishida; Tetsuro Sasada
Journal:  Oncotarget       Date:  2018-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.